GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (LTS:0IDA) » Definitions » EV-to-FCF

Dynavax Technologies (LTS:0IDA) EV-to-FCF : 20.58 (As of Mar. 31, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Dynavax Technologies EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Dynavax Technologies's Enterprise Value is $1,237.9 Mil. Dynavax Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $60.2 Mil. Therefore, Dynavax Technologies's EV-to-FCF for today is 20.58.

The historical rank and industry rank for Dynavax Technologies's EV-to-FCF or its related term are showing as below:

LTS:0IDA' s EV-to-FCF Range Over the Past 10 Years
Min: -39.95   Med: -2.65   Max: 66.18
Current: 20.58

During the past 13 years, the highest EV-to-FCF of Dynavax Technologies was 66.18. The lowest was -39.95. And the median was -2.65.

LTS:0IDA's EV-to-FCF is ranked better than
54.64% of 549 companies
in the Drug Manufacturers industry
Industry Median: 23.45 vs LTS:0IDA: 20.58

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-31), Dynavax Technologies's stock price is $13.7006. Dynavax Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.180. Therefore, Dynavax Technologies's PE Ratio (TTM) for today is 76.11.


Dynavax Technologies EV-to-FCF Historical Data

The historical data trend for Dynavax Technologies's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies EV-to-FCF Chart

Dynavax Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.26 4.42 17.84 13.74 18.99

Dynavax Technologies Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.74 21.86 27.91 41.88 18.99

Competitive Comparison of Dynavax Technologies's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynavax Technologies's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's EV-to-FCF falls into.


;
;

Dynavax Technologies EV-to-FCF Calculation

Dynavax Technologies's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1237.872/60.16
=20.58

Dynavax Technologies's current Enterprise Value is $1,237.9 Mil.
Dynavax Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $60.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dynavax Technologies  (LTS:0IDA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Dynavax Technologies's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.7006/0.180
=76.11

Dynavax Technologies's share price for today is $13.7006.
Dynavax Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.180.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Dynavax Technologies EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynavax Technologies Business Description

Traded in Other Exchanges
Address
2100 Powell Street, Suite 720, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies Headlines

No Headlines